What do systematic reviews say?

Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation

Chemotherapy plus involved‐field radiation showed no clear difference in death compared with same chemotherapy plus extended‐field radiation (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.89 [0.7, 1.12]
  4 studies · 2397 participants
  High

Chemotherapy plus involved‐field radiation vs same chemotherapy plus extended‐field radiation

Chemotherapy plus involved‐field radiation showed no clear difference in progression/relapse compared with same chemotherapy plus extended‐field radiation (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.99 [0.81, 1.21]
  4 studies · 2397 participants
  High

Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation

Chemotherapy plus lower‐dose radiation showed no clear difference in secondary malignant neoplasms compared with same chemotherapy plus higher‐dose radiation (low certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  OR 1.03 [0.71, 1.5]
  3 studies · 2962 participants
  Low

Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation

Chemotherapy plus lower‐dose radiation showed no clear difference in death compared with same chemotherapy plus higher‐dose radiation (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 0.91 [0.65, 1.28]
  3 studies · 2962 participants
  High

Chemotherapy plus lower‐dose radiation vs same chemotherapy plus higher‐dose radiation

Chemotherapy plus lower‐dose radiation showed no clear difference in progression/relapse compared with same chemotherapy plus higher‐dose radiation (high certainty).

• Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant… 2017 · Cochrane Headline outcomes only
  HR 1.2 [0.97, 1.48]
  3 studies · 2962 participants
  High

Intervention not reported

• Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer 2015 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1081 participants
  Low

Intervention not reported

The intervention showed no clear difference in year overall survival in patients of poor performance status (WHO… (moderate certainty).

• Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer 2015 · Cochrane Headline outcomes only
  RR 0.96 [0.91, 1.02]
  7 studies · 911 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in oesophagitis (grade 3 to 4) (low certainty).

• Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer 2015 · Cochrane Headline outcomes only
  RR 1.23 [0.81, 1.87]
  8 studies · 1301 participants
  Low

Intervention not reported

The intervention showed no clear difference in radiation Myelopathy (any grade) (moderate certainty).

• Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer 2015 · Cochrane Headline outcomes only
  RR 1.29 [0.37, 4.51]
  11 studies · 2663 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in radiation pneumonitis (any grade) (low certainty).

• Palliative radiotherapy regimens for patients with thoracic symptoms from non‐small cell lung cancer 2015 · Cochrane Headline outcomes only
  RR 0.62 [0.23, 1.66]
  3 studies · 533 participants
  Low

Intervention not reported

The intervention showed no clear difference in mortality (instead of OS) (moderate certainty).

• The role of additional radiotherapy for primary central nervous system lymphoma 2014 · Cochrane Headline outcomes only
  HR 1.01 [0.79, 1.3]
  1 study · 411 participants
  Moderate

Intervention not reported

The intervention may leads to lower relapses/death (instead of PFS) (low certainty).

• The role of additional radiotherapy for primary central nervous system lymphoma 2014 · Cochrane Headline outcomes only
  HR 0.79 [0.63, 0.99]
  1 study · 411 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• The role of additional radiotherapy for primary central nervous system lymphoma 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

It is very uncertain whether the intervention changes adverse events: treatment‐related neurotoxicity (very low certainty).

• The role of additional radiotherapy for primary central nervous system lymphoma 2014 · Cochrane Headline outcomes only
  RR 1.85 [0.98, 3.48]
  1 study · 79 participants
  Very low

Intervention not reported

• The role of additional radiotherapy for primary central nervous system lymphoma 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 84 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• The role of additional radiotherapy for primary central nervous system lymphoma 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in overall Survival (median (low certainty).

• Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
  HR 1.11 [0.83, 1.48]
  5 studies · 663 participants
  Low

Intervention not reported

The intervention showed no clear difference in progression free survival (low certainty).

• Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
  HR 0.76 [0.53, 1.1]
  2 studies · 378 participants
  Low

Intervention not reported

The intervention may leads to lower any intracranial disease progression at 1 year (low certainty).

• Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
  RR 0.46 [0.35, 0.6]
  4 studies · 304 participants
  Low

Intervention not reported

• Surgery or radiosurgery plus whole brain radiotherapy versus surgery or radiosurgery alone for brain metastases 2014 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 209 participants
  Low